Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain

Stroke. 2005 Oct;36(10):2220-5. doi: 10.1161/01.STR.0000182241.07096.06. Epub 2005 Sep 15.

Abstract

Background and purpose: Oxidative stress contributes to ischemia/reperfusion neuronal damage in a consecutive 2-phase pattern: an immediate direct cytotoxic effect and subsequent redox-mediated inflammatory insult. The present study was designed to assess the neuroprotective mechanisms of edaravone, a novel free radical scavenger, through antioxidative and anti-inflammatory pathways, from the early period to up to 7 days after ischemia/reperfusion in mice.

Methods: Mice were subjected to 60-minute ischemia followed by reperfusion. They were divided into the edaravone group (n=72; with different schedules for first administration) and the vehicle (control) group (n=36). Infarct volume and neurological deficit scores were evaluated at several time points after ischemia. Immunohistochemical analysis for 4-hydroxy-2-nonenal (HNE), 8-hydroxy-deoxyguanosine (8-OHdG), ionized calcium-binding adapter molecule 1 (Iba-1), inducible NO synthase (iNOS), and nitrotyrosine were performed at 24 hours, 72 hours, or 7 days after reperfusion.

Result: Edaravone, even when administrated 6 hours after onset of ischemia/reperfusion, significantly reduced the infarct volume (68.10+/-6.24%; P<0.05) and improved the neurological deficit scores (P<0.05) at 24 hours after reperfusion. Edaravone markedly suppressed the accumulation of HNE-modified protein and 8-OHdG at the penumbra area during the early period after reperfusion (P<0.05) and reduced microglial activation, iNOS expression, and nitrotyrosine formation at the late period.

Conclusions: Our results indicated that edaravone exerts an early neuroprotective effect through the early free radicals scavenging pathway and a late anti-inflammatory effect and suggested that edaravone is important for expansion of the therapeutic time window in stroke patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Hydroxy-2'-Deoxyguanosine
  • Aldehydes / pharmacology
  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Antioxidants / chemistry
  • Antioxidants / pharmacology
  • Antipyrine / analogs & derivatives*
  • Antipyrine / pharmacology
  • Brain / drug effects
  • Brain / pathology
  • Brain Ischemia / drug therapy*
  • Brain Ischemia / pathology*
  • DNA Damage
  • Deoxyguanosine / analogs & derivatives
  • Deoxyguanosine / pharmacology
  • Edaravone
  • Electrophoresis, Polyacrylamide Gel
  • Free Radical Scavengers / pharmacology*
  • Immunoblotting
  • Immunohistochemistry
  • Inflammation
  • Lipid Peroxidation
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neuroprotective Agents / pharmacology
  • Oxidative Stress
  • Reperfusion Injury / drug therapy*
  • Time Factors
  • Tyrosine / analogs & derivatives
  • Tyrosine / chemistry

Substances

  • Aldehydes
  • Anti-Inflammatory Agents
  • Antioxidants
  • Free Radical Scavengers
  • Neuroprotective Agents
  • 3-nitrotyrosine
  • Tyrosine
  • 8-Hydroxy-2'-Deoxyguanosine
  • Deoxyguanosine
  • 4-hydroxy-2-nonenal
  • Edaravone
  • Antipyrine